HANSHOW
13.6.2024 11:51:29 CEST | Business Wire | Press release
Hanshow, a global leader in Electronic Shelf Labels (ESL) and digital retail solutions, proudly participated in the first NRF Big Show 2024 Asia Pacific, held in Singapore from June 11-13. Organized by the National Retail Federation (NRF), this highly anticipated event marked a significant milestone in the retail industry, bringing together the best and brightest minds from around the world.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240612653287/en/
Hanshow at NRF APAC 2024 (Photo: Business Wire)
A Leap Forward in Shopper Experience and Store Operation
At this prestigious event, Hanshow introduced its Smart Cart Solution, developed with Microsoft on the Azure Open AI platform, leveraging Generative AI (GenAI) to enhance customer experience and store operations in a smarter, more connected retail ecosystem. This solution featured an AI copilot for personalized shopping, offering tailored recommendations and syncing online and in-store customer profiles for a seamless shopping experience.
Additionally, the Smart Cart enables skip-the-line checkout for faster, more convenient transactions. Retailers benefited from retail media revenue by displaying location-based advertisements and offering smart product recommendations, boosting their revenue. The solution also provided valuable data on shopper behavior and product performance.
In addition, Hanshow’s Lumina digital display series revolutionizes in-store marketing by integrating with GenAI, providing a state-of-the-art digital marketing solution. With the power of GPT-4 and DALL-E3, users can effortlessly craft product POP posters, atmospheric marketing visuals, and persuasive product copy through simple text commands.
"Our co-innovated solutions with Microsoft, showcased at this NRF, mark a significant step in revolutionizing the retail experience," said Shiguo Hou, CEO of Hanshow. "Together, we are not only redefining shopping but also empowering retailers with the tools to excel in a competitive landscape and forge a shared vision for the future. We’re honored to have jointly held our Retail Conference with Microsoft in Singapore, and our meeting with Microsoft APAC CEO Ahmed Mazhari discussed yielded new areas for possible future cooperation."
Sustainability and Growth Vision
Hanshow's vision for a greener future in retail outlines the steps businesses must take to balance decarbonization and sustainability with creating value for customers, employees, and stakeholders. A key component of this vision is the electronic shelf label (ESL) solution, which transforms retail operations by enabling dynamic pricing, real-time promotions, and efficient inventory management. ESLs help retailers significantly reduce their carbon footprint by minimizing food waste and enhancing resource efficiency.
Additionally, Hanshow has expanded its offerings with a digital energy solution. Key aspects of this solution include globally integrated local teams, R&D innovation, 24/7 butler service, a one-stop turnkey PV digital energy system, and flexible financing options with PPA resources. These initiatives drive sustainability and business growth by providing tailored PV, charging, and digital energy management systems.
Hanshow’s participation in NRF APAC underscored its commitment to driving innovation in the retail sector and supporting the digital transformation of retailers worldwide. The hands-on experience provided to attendees was a glimpse into a future where our technology is the cornerstone of a more intelligent, efficient, and eco-friendly retail landscape. As we move forward, Hanshow is committed to continuing to lead and support the global retail community in embracing transformative digital solutions that shape a sustainable and prosperous tomorrow.
About Hanshow
Hanshow is a global leader in developing and manufacturing electronic shelf labels and digital store solutions. The company offers customers a series of customized IoT touchpoints and digital store solutions that deliver customer-centric insights. Hanshow's solutions have provided services to a vast number of stores in over 50 countries and regions, helping them streamline operations, optimize pricing strategies, and offer consumers a more personalized experience. Learn more: www.hanshow.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240612653287/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom